• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低级别浆液性卵巢癌的分子亚型与组织病理学特征及预后相关。

Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma.

机构信息

Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XU, UK.

Department of Gynaecologic Oncology, The Netherlands Cancer Institute, Antoni Van Leeuwenhoek, Amsterdam, The Netherlands.

出版信息

Sci Rep. 2023 May 11;13(1):7681. doi: 10.1038/s41598-023-34627-5.

DOI:10.1038/s41598-023-34627-5
PMID:37169775
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10175560/
Abstract

Low grade serous ovarian carcinoma (LGSOC) demonstrates unique clinical and molecular features compared to other ovarian cancer types. The relationship between common histological features of LGSOC and molecular events, such as hormone receptor expression patterns and MAPK gene mutation status, remains poorly understood. Recent data suggest some of these molecular features may be biomarkers of response to recently introduced biologically-targeted therapies, namely endocrine therapy and MEK inhibitors. We utilize a cohort of 63 pathologically-confirmed LGSOC cases with whole exome sequencing and hormone receptor expression data to investigate these relationships. LGSOC cases demonstrated uniformly high oestrogen receptor (ER) expression, but variable progesterone receptor (PR) expression intensity. 60% and 37% of cases demonstrated micropapillary and macropapillary patterns of stromal invasion, respectively. 63% of cases demonstrated desmoplasia, which was significantly associated with advanced disease stage and visible residual disease after cytoreductive surgery. MAPK-mutant cases (KRAS, BRAF, NRAS) more frequently demonstrated macropapillary stromal invasion, while Chr1p loss was associated with desmoplasia and low PR expression. Presence of micropapillary stromal invasion and low PR expression were associated with significantly poorer survival after accounting for stage and residual disease status. Together, these data identify novel relationships between histopathological features and molecularly-defined subgroups in LGSOC.

摘要

低级别浆液性卵巢癌 (LGSOC) 与其他卵巢癌类型相比具有独特的临床和分子特征。LGSOC 的常见组织学特征与分子事件(如激素受体表达模式和 MAPK 基因突变状态)之间的关系尚未得到充分了解。最近的数据表明,其中一些分子特征可能是最近引入的生物靶向治疗(即内分泌治疗和 MEK 抑制剂)反应的生物标志物。我们利用一组经过全外显子测序和激素受体表达数据证实的 63 例病理 LGSOC 病例来研究这些关系。LGSOC 病例表现出均匀高的雌激素受体 (ER) 表达,但孕激素受体 (PR) 表达强度存在差异。分别有 60%和 37%的病例表现出微乳头状和大乳头状的基质浸润模式。63%的病例表现出间质增生,这与晚期疾病阶段和细胞减灭术后可见残留疾病显著相关。MAPK 突变病例(KRAS、BRAF、NRAS)更频繁地表现出大乳头状基质浸润,而 Chr1p 缺失与间质增生和 PR 低表达相关。考虑到分期和残留疾病状态,存在微乳头状基质浸润和 PR 低表达与生存率显著降低相关。这些数据共同确定了 LGSOC 中组织病理学特征与分子定义亚组之间的新关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9666/10175560/3eb4aa9ba607/41598_2023_34627_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9666/10175560/037a0f27e2f7/41598_2023_34627_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9666/10175560/272bf0c7e99f/41598_2023_34627_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9666/10175560/08858f6b65d2/41598_2023_34627_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9666/10175560/dc367a6b8efc/41598_2023_34627_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9666/10175560/3eb4aa9ba607/41598_2023_34627_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9666/10175560/037a0f27e2f7/41598_2023_34627_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9666/10175560/272bf0c7e99f/41598_2023_34627_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9666/10175560/08858f6b65d2/41598_2023_34627_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9666/10175560/dc367a6b8efc/41598_2023_34627_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9666/10175560/3eb4aa9ba607/41598_2023_34627_Fig5_HTML.jpg

相似文献

1
Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma.低级别浆液性卵巢癌的分子亚型与组织病理学特征及预后相关。
Sci Rep. 2023 May 11;13(1):7681. doi: 10.1038/s41598-023-34627-5.
2
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.激素受体表达与卵巢癌生存:卵巢肿瘤组织分析联盟研究。
Lancet Oncol. 2013 Aug;14(9):853-62. doi: 10.1016/S1470-2045(13)70253-5. Epub 2013 Jul 9.
3
Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.低级别浆液性卵巢癌的全外显子组测序鉴定与临床结局相关的基因组事件。
Gynecol Oncol. 2023 Jul;174:157-166. doi: 10.1016/j.ygyno.2023.04.011. Epub 2023 May 17.
4
A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma.低级别浆液性卵巢癌中激素受体表达的系统评价与荟萃分析
Eur J Obstet Gynecol Reprod Biol. 2021 Jan;256:172-178. doi: 10.1016/j.ejogrb.2020.11.021. Epub 2020 Nov 12.
5
Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.低级别浆液性卵巢癌和腹膜癌的进展。
Curr Oncol Rep. 2022 Nov;24(11):1549-1555. doi: 10.1007/s11912-022-01315-y. Epub 2022 Aug 13.
6
Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.低级别浆液性卵巢癌的基因组分析,以鉴定关键驱动因素和治疗弱点。
J Pathol. 2021 Jan;253(1):41-54. doi: 10.1002/path.5545. Epub 2020 Oct 28.
7
Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.多组学分析低级别浆液性卵巢癌,鉴定潜在的 MEK 抑制剂敏感性和治疗敏感性生物标志物。
Cancer Res. 2021 Apr 1;81(7):1681-1694. doi: 10.1158/0008-5472.CAN-20-2222. Epub 2021 Jan 13.
8
Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.Ki-67 水平和激素受体表达在低级别浆液性卵巢癌中的预后意义:肿瘤银行卵巢癌网络的研究。
Hum Pathol. 2019 Mar;85:299-308. doi: 10.1016/j.humpath.2018.10.020. Epub 2018 Nov 11.
9
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.低级别浆液性卵巢/腹膜癌的基因组特征及其对临床结局的影响。
Gynecol Oncol. 2022 Jun;165(3):560-567. doi: 10.1016/j.ygyno.2021.11.019. Epub 2022 Mar 30.
10
Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.低级别浆液性卵巢癌的基因组分析:用于疾病诊断和治疗的新型标志物的鉴定。
Gynecol Oncol. 2022 Nov;167(2):306-313. doi: 10.1016/j.ygyno.2022.09.022. Epub 2022 Oct 11.

引用本文的文献

1
AEG-1 expression analysis in epithelial ovarian carcinoma: Uncovering distinctions between high-grade and low-grade serous carcinoma.上皮性卵巢癌中AEG-1表达分析:揭示高级别与低级别浆液性癌之间的差异
Mol Clin Oncol. 2025 Jun 4;23(2):70. doi: 10.3892/mco.2025.2865. eCollection 2025 Aug.
2
Editorial: Advances toward improved understanding and treatment of uncommon ovarian cancer types and subtypes.社论:在深入了解和治疗罕见卵巢癌类型及亚型方面取得的进展
Front Oncol. 2024 Dec 9;14:1519252. doi: 10.3389/fonc.2024.1519252. eCollection 2024.
3
The survival benefit associated with complete macroscopic resection in epithelial ovarian cancer is histotype specific.

本文引用的文献

1
Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.低级别浆液性卵巢癌的全外显子组测序鉴定与临床结局相关的基因组事件。
Gynecol Oncol. 2023 Jul;174:157-166. doi: 10.1016/j.ygyno.2023.04.011. Epub 2023 May 17.
2
Molecular characteristics and clinical behaviour of epithelial ovarian cancers.上皮性卵巢癌的分子特征和临床行为。
Cancer Lett. 2023 Feb 28;555:216057. doi: 10.1016/j.canlet.2023.216057. Epub 2023 Jan 7.
3
Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.
上皮性卵巢癌中完全肉眼切除与生存获益相关,具有组织学类型特异性。
JNCI Cancer Spectr. 2024 Jul 1;8(4). doi: 10.1093/jncics/pkae049.
4
Ovarian carcinosarcoma is highly aggressive compared to other ovarian cancer histotypes.与其他组织学类型的卵巢癌相比,卵巢癌肉瘤具有高度侵袭性。
Front Oncol. 2024 May 24;14:1399979. doi: 10.3389/fonc.2024.1399979. eCollection 2024.
低级别浆液性卵巢癌的基因组分析:用于疾病诊断和治疗的新型标志物的鉴定。
Gynecol Oncol. 2022 Nov;167(2):306-313. doi: 10.1016/j.ygyno.2022.09.022. Epub 2022 Oct 11.
4
NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.NOTCH 信号限制低级别浆液性卵巢癌对 MEK 抑制的反应。
Mol Cancer Ther. 2022 Dec 2;21(12):1862-1874. doi: 10.1158/1535-7163.MCT-22-0004.
5
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
6
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.NCCN 指南®洞察:卵巢癌,第 3.2022 版。
J Natl Compr Canc Netw. 2022 Sep;20(9):972-980. doi: 10.6004/jnccn.2022.0047.
7
Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma.卵巢癌肉瘤是一种独特的卵巢癌形式,与输卵管-卵巢高级别浆液性癌相比,其生存率较差。
Br J Cancer. 2022 Oct;127(6):1034-1042. doi: 10.1038/s41416-022-01874-8. Epub 2022 Jun 17.
8
Laparoscopic Ultra-radical Lymph Node Debulking Using Yasargil Clamps for Gynecological Malignancies: Results from a Large, Multicenter, Retrospective Analysis.腹腔镜下用 Yasargil 夹行妇科恶性肿瘤超根治性淋巴结切除术:一项大型多中心回顾性分析的结果。
J Minim Invasive Gynecol. 2022 Sep;29(9):1083-1091. doi: 10.1016/j.jmig.2022.05.016. Epub 2022 May 29.
9
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.低级别浆液性卵巢/腹膜癌的基因组特征及其对临床结局的影响。
Gynecol Oncol. 2022 Jun;165(3):560-567. doi: 10.1016/j.ygyno.2021.11.019. Epub 2022 Mar 30.
10
Cervical versus Utero-Ovarian Ligament Injection of the Tracer for the Pelvic Sentinel Lymph Node Mapping in Gynecologic Oncology: A Prospective Observational Study.妇科肿瘤学中盆腔前哨淋巴结图谱绘制示踪剂的宫颈注射与子宫卵巢韧带注射:一项前瞻性观察研究
Gynecol Obstet Invest. 2022;87(3-4):242-247. doi: 10.1159/000525126. Epub 2022 May 18.